These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28983968)

  • 21. [Susceptibility to 6-mercaptopurine toxicity related with NUDT15 and ABCC4 variants in Japanese childhood acute lymphoblastic leukemia].
    Tanaka Y
    Rinsho Ketsueki; 2017; 58(8):950-956. PubMed ID: 28883280
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Minimal residual disease analysis in acute lymphoblastic leukemia of childhood within the framework of COALL Study: results of an induction therapy without asparaginase].
    zur Stadt U; Harms DO; Schlüter S; Jorch N; Spaar HJ; Nürnberger W; Völpel S; Gutjahr P; Schrappe M; Janka G; Kabisch H
    Klin Padiatr; 2000; 212(4):169-73. PubMed ID: 10994545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG.
    van der Werff Ten Bosch J; Suciu S; Thyss A; Bertrand Y; Norton L; Mazingue F; Uyttebroeck A; Lutz P; Robert A; Boutard P; Ferster A; Plouvier E; Maes P; Munzer M; Plantaz D; Dresse MF; Philippet P; Sirvent N; Waterkeyn C; Vilmer E; Philippe N; Otten J
    Leukemia; 2005 May; 19(5):721-6. PubMed ID: 15744348
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance Treatment With Low-Dose Mercaptopurine in Combination With Allopurinol in Children With Acute Lymphoblastic Leukemia and Mercaptopurine-Induced Pancreatitis.
    Zerra P; Bergsagel J; Keller FG; Lew G; Pauly M
    Pediatr Blood Cancer; 2016 Apr; 63(4):712-5. PubMed ID: 26878433
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of allopurinol on 6-mercaptopurine metabolism in unselected patients with pediatric acute lymphoblastic leukemia: a prospective phase II study.
    Källström J; Niinimäki R; Fredlund J; Vogt H; Korhonen L; Castor A; Palle J; Harila A; Borssén M; Abrahamsson J; Ek T
    Haematologica; 2024 Sep; 109(9):2846-2853. PubMed ID: 38356449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Thioguanine offers no advantage over mercaptopurine in maintenance treatment of childhood ALL: results of the randomized trial COALL-92.
    Harms DO; Göbel U; Spaar HJ; Graubner UB; Jorch N; Gutjahr P; Janka-Schaub GE;
    Blood; 2003 Oct; 102(8):2736-40. PubMed ID: 12843002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
    Winter SS; Holdsworth MT; Devidas M; Raisch DW; Chauvenet A; Ravindranath Y; Ducore JM; Amylon MD
    Pediatr Blood Cancer; 2006 Feb; 46(2):179-86. PubMed ID: 16007607
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical efficacy and safety of 6-thioguanine in the treatment of childhood acute lymphoblastic leukemia: A protocol for systematic review and meta-analysis.
    Chen L; Yan HX; Liu XW; Chen WX
    Medicine (Baltimore); 2020 May; 99(18):e20082. PubMed ID: 32358392
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood.
    van Dongen JJ; Seriu T; Panzer-Grümayer ER; Biondi A; Pongers-Willemse MJ; Corral L; Stolz F; Schrappe M; Masera G; Kamps WA; Gadner H; van Wering ER; Ludwig WD; Basso G; de Bruijn MA; Cazzaniga G; Hettinger K; van der Does-van den Berg A; Hop WC; Riehm H; Bartram CR
    Lancet; 1998 Nov; 352(9142):1731-8. PubMed ID: 9848348
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of continuous-infusion 6-mercaptopurine for childhood leukemia.
    Adamson PC; Zimm S; Ragab AH; Balis F; Steinberg SM; Kamen BA; Vietti TJ; Gillespie A; Poplack DG
    Cancer Chemother Pharmacol; 1992; 30(2):155-7. PubMed ID: 1600597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Individualized Use of 6-Mercaptopurine in Chinese Children with ALL: A Multicenter Randomized Controlled Trial.
    Zhou Y; Wang L; Sun LR; Zhang L; Wang HM; Liu XT; Yang F; Wu KL; Liang YL; Zhao BB; Zhuang Y; Fu JQ; Song C; Li Y; Wang LZ; Xu HJ; Gu Y; van den Anker J; Ju XL; Zhu XF; Zhao W
    Clin Pharmacol Ther; 2024 Feb; 115(2):213-220. PubMed ID: 37753808
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mercaptopurine in childhood leukaemia: the effects of dose escalation on thioguanine nucleotide metabolites.
    Lennard L; Welch J; Lilleyman JS
    Br J Clin Pharmacol; 1996 Oct; 42(4):525-7. PubMed ID: 8904630
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ALL-REZ BFM--the consecutive trials for children with relapsed acute lymphoblastic leukemia.
    Henze G; v Stackelberg A; Eckert C
    Klin Padiatr; 2013 May; 225 Suppl 1():S73-8. PubMed ID: 23700062
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antagonism by methotrexate on mercaptopurine disposition in lymphoblasts during up-front treatment of acute lymphoblastic leukemia.
    Dervieux T; Hancock ML; Pui CH; Rivera GK; Sandlund JT; Ribeiro RC; Boyett J; Evans WE; Relling MV
    Clin Pharmacol Ther; 2003 Jun; 73(6):506-16. PubMed ID: 12811360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Does intravenous 6-mercaptopurine decrease salvage after relapse in childhood acute lymphoblastic leukemia?
    Mahoney DH; Camitta BM; Devidas M
    Pediatr Blood Cancer; 2006 May; 46(5):660-1. PubMed ID: 16276523
    [No Abstract]   [Full Text] [Related]  

  • 36. [Acute lymphoblastic leukemia: a genomic perspective].
    Jiménez-Morales S; Hidalgo-Miranda A; Ramírez-Bello J
    Bol Med Hosp Infant Mex; 2017; 74(1):13-26. PubMed ID: 29364809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Research advances in pharmacogenomics of mercaptopurine].
    Chen XX; Shen SH
    Zhongguo Dang Dai Er Ke Za Zhi; 2017 Sep; 19(9):1027-1033. PubMed ID: 28899477
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Six months of maintenance chemotherapy after intensified treatment for acute lymphoblastic leukemia of childhood.
    Toyoda Y; Manabe A; Tsuchida M; Hanada R; Ikuta K; Okimoto Y; Ohara A; Ohkawa Y; Mori T; Ishimoto K; Sato T; Kaneko T; Maeda M; Koike Ki; Shitara T; Hoshi Y; Hosoya R; Tsunematsu Y; Bessho F; Nakazawa S; Saito T
    J Clin Oncol; 2000 Apr; 18(7):1508-16. PubMed ID: 10735899
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia.
    Estlin EJ; Lowis SP; Hall AG
    Br J Haematol; 2000 Jul; 110(1):29-40. PubMed ID: 10930977
    [No Abstract]   [Full Text] [Related]  

  • 40. Clofarabine increases the eradication of minimal residual disease of primary B-precursor acute lymphoblastic leukemia compared to high-dose cytarabine without improvement of outcome. Results from the randomized clinical trial 08-09 of the Cooperative Acute Lymphoblastic Leukemia Study Group.
    Escherich G; Zur Stadt U; Borkhardt A; Dilloo D; Faber J; Feuchtinger T; Imschweiler T; Jorch N; Pekrun A; Schmid I; Schramm F; Spohn M; Zimmermann M; Horstmann MA
    Haematologica; 2022 May; 107(5):1026-1033. PubMed ID: 34348455
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.